2024-03-28T17:12:43Zhttp://digital.csic.es/dspace-oai/requestoai:digital.csic.es:10261/2212062022-11-24T12:26:52Zcom_10261_134com_10261_1col_10261_387
Soria-Juan, Bárbara
Escacena, Natalia
Capilla-González, Vivian
Aguilera, Yolanda
Llanos, Lucía
Tejedo Huamán, Juan Rigoberto
Bedoya Bergua, Francisco Javier
Juan, Verónica
Cuesta, Antonio de la
Ruiz-Salmerón, Rafael
Andreu, Enrique
Grochowicz, Lukas
Prósper, Felipe
Sánchez-Guijo, Fermín
Lozano, Francisco S.
Miralles, Manuel
Río-Solá, Lourdes del
Castellanos, Gregorio
Moraleda, José M.
Sackstein, Robert
García-Arranz, Mariano
García-Olmo, Damián
Martín, Franz
Hmadcha, Abdelkrim
Soria Escoms, Bernat
2020-10-15T06:37:19Z
2020-10-15T06:37:19Z
2019
Frontiers in Immunology 10: 1151 (2019)
http://hdl.handle.net/10261/221206
10.3389/fimmu.2019.01151
1664-3224
http://dx.doi.org/10.13039/501100000780
http://dx.doi.org/10.13039/501100004587
http://dx.doi.org/10.13039/100008664
http://dx.doi.org/10.13039/501100011011
31231366
Cell therapy is a progressively growing field that is rapidly moving from preclinical model development to clinical application. Outcomes obtained from clinical trials reveal the therapeutic potential of stem cell-based therapy to deal with unmet medical treatment needs for several disorders with no therapeutic options. Among adult stem cells, mesenchymal stem cells (MSCs) are the leading cell type used in advanced therapies for the treatment of autoimmune, inflammatory and vascular diseases. To date, the safety and feasibility of autologous MSC-based therapy has been established; however, their indiscriminate use has resulted in mixed outcomes in preclinical and clinical studies. While MSCs derived from diverse tissues share common properties depending on the type of clinical application, they markedly differ within clinical trials in terms of efficacy, resulting in many unanswered questions regarding the application of MSCs. Additionally, our experience in clinical trials related to critical limb ischemia pathology (CLI) shows that the therapeutic efficacy of these cells in different animal models has only been partially reproduced in humans through clinical trials. Therefore, it is crucial to develop new research to identify pitfalls, to optimize procedures and to clarify the repair mechanisms used by these cells, as well as to be able to offer a next generation of stem cell that can be routinely used in a cost-effective and safe manner in stem cell-based therapies targeting CLI.
eng
http://creativecommons.org/licenses/by/4.0/
openAccess
Cost-effective, safe, and personalized cell therapy for critical limb ischemia in type 2 diabetes mellitus
artículo